After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and ... will approach the end of its patent life.
Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Cycling News on MSN5d
Patent pending: How patents steer innovation in cyclingAt times, the cycling patent news cycle feels intense and a little relentless. A patent for exciting new components or some ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
The lawsuit, filed Tuesday in U.S. District Court in Delaware, is the latest in a series of patent challenges against ...
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback